Aliases & Classifications for Osteonecrosis

Summaries for Osteonecrosis

MedlinePlus : 43 Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well. No one is sure what causes the disease. Risk factors include Long-term steroid treatment Alcohol abuse Joint injuries Having certain diseases, including arthritis and cancer Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteonecrosis, also known as bone necrosis, is related to osteonecrosis of the jaw and legg-calve-perthes disease, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Rheumatoid arthritis. The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone and bone marrow, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 An ischemic bone disease that results in necrosis located in bone.

Wikipedia : 76 Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to... more...

Related Diseases for Osteonecrosis

Diseases related to Osteonecrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis of the jaw 33.8 CYP2C8 FDPS VEGFA
2 legg-calve-perthes disease 32.6 COL2A1 SERPINC1 SERPINE1
3 thrombophilia 30.5 F2 MTHFR SERPINC1 SERPINE1
4 osteoporotic fracture 30.5 MTHFR TNFRSF11B
5 myeloma, multiple 30.4 ABCB1 TNFRSF11B TNFSF11 VEGFA
6 disseminated intravascular coagulation 30.3 F2 SERPINC1 SERPINE1
7 protein s deficiency 30.3 F2 MTHFR SERPINC1
8 kummell's disease 30.3 TNFRSF11B TNFSF11
9 antithrombin iii deficiency 30.1 F2 MTHFR SERPINC1
10 osteomyelitis 30.1 ACP5 BMP2 TNFSF11
11 protein c deficiency 30.1 F2 MTHFR SERPINC1
12 villonodular synovitis 30.0 ACP5 TNFSF11
13 giant cell tumor 29.7 BGLAP TNFRSF11B TNFSF11
14 periodontitis 29.7 BGLAP RUNX2 TNFRSF11B TNFSF11
15 renal osteodystrophy 29.5 BGLAP PTH TNFRSF11B
16 vascular disease 28.9 F2 MTHFR SERPINC1 SERPINE1 TNFRSF11B VEGFA
17 paget's disease of bone 27.5 ACP5 BGLAP PTH TNFRSF11B TNFSF11
18 glucocorticoid-induced osteoporosis 26.3 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
19 bone disease 25.6 ACP5 BGLAP BMP7 COL2A1 PTH RUNX2
20 osteoporosis 25.0 ACP5 BGLAP BMP2 COL2A1 CYP3A4 FDPS
21 dysbaric osteonecrosis 12.3
22 avascular necrosis of femoral head, primary, 1 11.6
23 familial avascular necrosis of the femoral head 11.4
24 freiberg's disease 11.2
25 inferior vena cava interruption 11.0 MTHFR SERPINE1
26 neonatal stroke 10.9 MTHFR SERPINE1
27 amaurosis fugax 10.9 MTHFR SERPINE1
28 hemifacial spasm 10.9 MTHFR VEGFA
29 mesenteric vascular occlusion 10.9 F2 MTHFR
30 thiemann disease 10.9
31 gaucher disease, type iii 10.9
32 kienbock's disease 10.9
33 livedoid vasculopathy 10.8 F2 MTHFR SERPINE1
34 fibrinolytic defect 10.8 SERPINC1 SERPINE1
35 cryptogenic cirrhosis 10.7 F2 MTHFR SERPINE1
36 buerger disease 10.7 F2 MTHFR SERPINE1
37 mucositis 10.7 ABCB1 MTHFR VEGFA
38 intestinal impaction 10.7 F2 SERPINC1
39 fournier gangrene 10.7 F2 SERPINC1
40 polyarticular onset juvenile idiopathic arthritis 10.6 TNFRSF11B TNFSF11
41 nutritional deficiency disease 10.6 BGLAP F2 MTHFR
42 argentine hemorrhagic fever 10.6 SERPINC1 SERPINE1
43 ischemic neuropathy 10.6 F2 MTHFR
44 spinal cord infarction 10.6 F2 MTHFR SERPINC1
45 sudden sensorineural hearing loss 10.6 F2 MTHFR SERPINC1
46 blood protein disease 10.6 F2 MTHFR SERPINC1
47 hemangioma of liver 10.6 CYP3A4 F2
48 sticky platelet syndrome 10.6 SERPINC1 SERPINE1
49 osteopetrosis, autosomal dominant 2 10.6 BGLAP TNFSF11
50 marantic endocarditis 10.6 F2 MTHFR SERPINC1

Graphical network of the top 20 diseases related to Osteonecrosis:



Diseases related to Osteonecrosis

Symptoms & Phenotypes for Osteonecrosis

UMLS symptoms related to Osteonecrosis:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Osteonecrosis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 BMP7 ABCB1 COL2A1 BMP2 F2 SERPINC1
2 growth/size/body region MP:0005378 10.23 BMP2 F2 MTHFR BMP7 ABCB1 COL2A1
3 hematopoietic system MP:0005397 10.17 BMP2 F2 BMP7 ABCB1 RUNX2 TNFSF11
4 immune system MP:0005387 10.15 F2 BMP7 ABCB1 COL2A1 BMP2 TNFSF11
5 homeostasis/metabolism MP:0005376 10.14 BMP2 F2 MTHFR ABCB1 COL2A1 RUNX2
6 craniofacial MP:0005382 10.1 BMP7 COL2A1 BMP2 RUNX2 TNFSF11 PTH
7 mortality/aging MP:0010768 10.07 BMP2 F2 MTHFR BMP7 ABCB1 COL2A1
8 digestive/alimentary MP:0005381 10.02 BMP2 F2 BMP7 ABCB1 COL2A1 RUNX2
9 limbs/digits/tail MP:0005371 9.97 BMP7 MTHFR COL2A1 BMP2 TNFSF11 VEGFA
10 reproductive system MP:0005389 9.81 BMP2 F2 MTHFR BMP7 ABCB1 RUNX2
11 respiratory system MP:0005388 9.5 F2 BMP7 COL2A1 RUNX2 TNFSF11 SERPINE1
12 skeleton MP:0005390 9.32 F2 BMP7 MTHFR COL2A1 BMP2 TNFSF11

Drugs & Therapeutics for Osteonecrosis

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 1 121268-17-5, 66376-36-1 2088
2
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
3
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
4
Dalteparin Approved Phase 4 9005-49-6
5
Enoxaparin Approved Phase 4 9005-49-6 772
6
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
7
Rivaroxaban Approved Phase 4 366789-02-8
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
9
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3 1406-66-2 14986
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
11
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
12 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
16 Antioxidants Phase 4,Phase 3
17 Micronutrients Phase 4,Phase 3,Phase 2
18 Phosphodiesterase Inhibitors Phase 4,Phase 3
19 Platelet Aggregation Inhibitors Phase 4,Phase 3
20 Protective Agents Phase 4,Phase 3
21 Radiation-Protective Agents Phase 4,Phase 3
22 Tocopherols Phase 4,Phase 3
23 Tocotrienols Phase 4,Phase 3
24 Trace Elements Phase 4,Phase 3,Phase 2
25 Vasodilator Agents Phase 4,Phase 3
26 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
27 Anticoagulants Phase 4
28 Antithrombin III Phase 4
29 Antithrombins Phase 4
30 calcium heparin Phase 4
31 Factor Xa Inhibitors Phase 4
32 Heparin, Low-Molecular-Weight Phase 4
33 HIV Protease Inhibitors Phase 4
34
protease inhibitors Phase 4
35 Serine Proteinase Inhibitors Phase 4
36 Pharmaceutical Solutions Phase 4,Not Applicable
37 Ferrosoferric Oxide Phase 4,Not Applicable
38 Hematinics Phase 4,Not Applicable
39 Parenteral Nutrition Solutions Phase 4,Not Applicable
40 Adjuvants, Immunologic Phase 4
41 Viscosupplements Phase 4
42 Tocotrienol Investigational, Nutraceutical Phase 4,Phase 3 6829-55-6
43
Etoposide Approved Phase 3 33419-42-0 36462
44
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
45
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
46
Denosumab Approved Phase 3,Phase 1,Phase 2 615258-40-7
47
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
48
Gemcitabine Approved Phase 3 95058-81-4 60750
49
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
50
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4 Alendronate
2 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
3 Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings Completed NCT01806766 Phase 4
4 A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Completed NCT01345097 Phase 4
5 Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old Completed NCT02338596 Phase 4
6 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4 Alendronate
7 Management of Mandibular ORN: PENTO as Medical Treatment Completed NCT02368457 Phase 4 Pentoxifylline and Tocopherol
8 Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty Completed NCT02379663 Phase 4 Rivaroxaban;Enoxaparin
9 Benefit of Orthopedic Navigation in the ARThroplasty of the Hip Completed NCT01496300 Phase 4
10 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Recruiting NCT02893293 Phase 4 Ferumoxytol-enhanced magnetic resonance imaging
11 Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis Recruiting NCT02984228 Phase 4 Hyaluronic Acid
12 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
13 Optetrak Posterior Stabilized Versus Optetrak Hi-Flex Withdrawn NCT00808613 Phase 4
14 Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH) Unknown status NCT01613612 Phase 2, Phase 3
15 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
16 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
17 Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial Completed NCT00532220 Phase 3 Ibandronate IV;Placebo
18 Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head Completed NCT00939900 Phase 3 zoledronic acid (aclasta)
19 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed NCT00523341 Phase 3
20 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
21 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
22 N-Acetylcysteine in Patients With Sickle Cell Disease Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
23 Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip Recruiting NCT03405974 Phase 3 Aspirin;Placebo
24 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Recruiting NCT01529008 Phase 3 Core decompression/PREOB® implantation;Core decompression/placebo implantation
25 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
26 Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Recruiting NCT02684708 Phase 3 cyclophosphamide, vincristine, prednisone, dacarbazine;cyclo, vcr, pred, dacarb,etop and doxo
27 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
28 Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies Recruiting NCT03408652 Phase 3 denosumab
29 Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy. Recruiting NCT02609828 Phase 3 Tanezumab
30 Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head Active, not recruiting NCT01892514 Phase 3
31 ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee Active, not recruiting NCT01458782 Phase 2, Phase 3
32 Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2) Active, not recruiting NCT01908751 Phase 3 Vitamin D;Vitamin D Placebo
33 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3 zoledronic acid
34 Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. Active, not recruiting NCT02709486 Phase 3 Tanezumab;Tanezumab;Placebo
35 Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease Enrolling by invitation NCT02536755 Phase 3 eliglustat GZ385660
36 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw Not yet recruiting NCT03390777 Phase 2, Phase 3
37 Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Terminated NCT02114489 Phase 3 ibandronate;Placebo
38 Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma Terminated NCT02739594 Phase 3 Ibandronate;Zoledronate
39 A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement Terminated NCT00208468 Phase 3
40 Osteonecrosis of the Hip and Bisphosphonate Treatment Unknown status NCT00781261 Phase 2 Zoledronic Acid;Placebo
41 MBCP Safety and Performance in the Osteonecrosis of Femur Head Unknown status NCT00289575 Phase 2
42 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Completed NCT00505219 Phase 2
43 PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells Completed NCT01700920 Phase 2
44 Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head Completed NCT02890537 Phase 2 Core decompression/PREOB® implantation;Core decompression/BMC implantation
45 Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty Completed NCT01622465 Phase 2
46 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents Completed NCT00921557 Phase 2 Alendronate;Placebo
47 Shock Wave Therapy for Osteoporosis Completed NCT02630381 Phase 2
48 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed NCT00996801 Phase 2 MK-5442;Placebo to MK-5442;Alendronate Sodium;Vitamin D3;Calcium carbonate;Placebo to Alendronate
49 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy
50 Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery Completed NCT00393848 Phase 2 Essential amino acid supplement;Ketoconazole;Placebo

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteonecrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteonecrosis:
JACC
PREOB
Embryonic/Adult Cultured Cells Related to Osteonecrosis:
Cultured cartilage (JACC PMIDs: 16233778 19393556 10738867 16226641 11284883 12043781 16233853 19802670 10679677

Cochrane evidence based reviews: osteonecrosis

Genetic Tests for Osteonecrosis

Anatomical Context for Osteonecrosis

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:

19
Bone

MalaCards organs/tissues related to Osteonecrosis:

41
Bone, Bone Marrow, Testes, Skin, Endothelial, Prostate, Kidney

Publications for Osteonecrosis

Articles related to Osteonecrosis:

(show top 50) (show all 1120)
# Title Authors Year
1
Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. ( 29955628 )
2018
2
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )
2018
3
Comment on: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29799056 )
2018
4
Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review. ( 29977926 )
2018
5
Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteenA year follow-up. ( 29594456 )
2018
6
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
7
Association of common comorbidities with osteonecrosis: a nationwide population-based case-control study in Denmark. ( 29439082 )
2018
8
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. ( 29211870 )
2018
9
Short stem survival after osteonecrosis of the femoral head. ( 29396635 )
2018
10
Enhanced bone defect repairing effects in glucocorticoid-induced osteonecrosis of the femoral head using a porous nano-lithium-hydroxyapatite/gelatin microsphere/erythropoietin composite scaffold. ( 29369309 )
2018
11
Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. ( 29870295 )
2018
12
Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. ( 29362430 )
2018
13
Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. ( 29729428 )
2018
14
Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw. ( 29422306 )
2018
15
Machine learning to predict the occurrence of bisphosphonate-related osteonecrosis of the jaw associated with dental extraction: A preliminary report. ( 29698784 )
2018
16
The biological basis for concentrated iliac crest aspirate to enhance core decompression in the treatment of osteonecrosis. ( 29435623 )
2018
17
Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain. ( 29952419 )
2018
18
Correction to : Hip osteonecrosis: stem cells for life or behead and arthroplasty? ( 29934718 )
2018
19
Diving, Dysbaric Osteonecrosis ( 29493935 )
2018
20
Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )
2018
21
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. ( 29325851 )
2018
22
Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. ( 29747794 )
2018
23
Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-NaA^ve Patient: A Comprehensive Review of the Literature. ( 29850569 )
2018
24
Pyogenic arthritis pyoderma gangrenosum and acne syndrome: A rare but important diagnosis for antibiotic-resistant erysipelas-like erythema and osteonecrosis. ( 29943877 )
2018
25
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. ( 29861164 )
2018
26
Thrombophilia-Associated Factors in Patients with Spontaneous Osteonecrosis of the Knee. ( 29308659 )
2018
27
Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions. ( 29432652 )
2018
28
Accuracy of MRI diagnosis of early osteonecrosis of the femoral head: a meta-analysis and systematic review. ( 29973239 )
2018
29
Comment on "Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw" by Lemound etA al. ( 29902417 )
2018
30
The association with xerostomia from sialadenitis and the jaw osteonecrosis in head and neck cancer population: a nationwide cohort study. ( 29725850 )
2018
31
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. ( 29289789 )
2018
32
FGF2 and FAM201A affect the development of osteonecrosis of the femoral head after femoral neck fracture. ( 29382571 )
2018
33
Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. ( 29408511 )
2018
34
Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. ( 29943905 )
2018
35
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? ( 29860712 )
2018
36
Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5A years of experience. ( 29948937 )
2018
37
A new 3D printed titanium metal trabecular bone reconstruction system for early osteonecrosis of the femoral head. ( 29952948 )
2018
38
Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw. ( 29857915 )
2018
39
The role of the subchondral layer in osteonecrosis of the femoral head: analysis based on HR-QCT in comparison to MRI findings. ( 29979104 )
2018
40
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. ( 29713913 )
2018
41
High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. ( 29394948 )
2018
42
Auto-Fluorescence and Histopathologic Evaluation of Medication-Related Osteonecrosis of the Jaws: Perspectives for Treatment. ( 29944562 )
2018
43
Authors' reply: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29796683 )
2018
44
Extravascular Hydrophobic Surfaces, Fat Droplets, and the Connection With Decompression Illness: Spinal, Joint Pain, and Dysbaric Osteonecrosis. ( 29636703 )
2018
45
Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. ( 29723337 )
2018
46
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. ( 29694412 )
2018
47
Duration of treatment with bisphosphonates at the time of osteonecrosis of the jaw onset in patients with rheumatoid arthritis. Review. ( 29325766 )
2018
48
Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. ( 29952657 )
2018
49
Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care. ( 29932939 )
2018
50
New method of alloplastic reconstruction of the mandible after subtotal mandibulectomy for medication-related osteonecrosis of the jaw. ( 29751943 )
2018

Variations for Osteonecrosis

Expression for Osteonecrosis

Search GEO for disease gene expression data for Osteonecrosis.

Pathways for Osteonecrosis

Pathways related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 11.78 BGLAP PTH RUNX2 TNFSF11
2 11.71 ACP5 TNFSF11 VEGFA
3
Show member pathways
11.68 ABCB1 CYP2C8 CYP3A4
4
Show member pathways
11.63 ABCB1 CYP2C8 CYP3A4
5
Show member pathways
11.57 BMP2 BMP7 RUNX2
6 11.51 ABCB1 SERPINE1 VEGFA
7
Show member pathways
11.48 ABCB1 CYP2C8 CYP3A4
8
Show member pathways
11.42 ABCB1 CYP2C8 CYP3A4
9
Show member pathways
11.39 ABCB1 CYP2C8 CYP3A4
10 11.37 BMP7 COL2A1 PTH RUNX2 VEGFA
11 11.15 BGLAP PTH RUNX2 TNFSF11
12
Show member pathways
10.99 ABCB1 CYP2C8 CYP3A4
13 10.83 ABCB1 CYP3A4
14 10.78 ACP5 TNFRSF11B TNFSF11
15 10.77 ABCB1 CYP3A4
16 10.76 BGLAP F2
17 10.75 BGLAP CYP3A4 PTH RUNX2 TNFRSF11B TNFSF11
18 10.72 ABCB1 CYP2C8 CYP3A4
19 10.61 ABCB1 CYP2C8 CYP3A4
20 10.55 ABCB1 CYP3A4
21 10.4 BGLAP PTH TNFRSF11B TNFSF11

GO Terms for Osteonecrosis

Cellular components related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 BGLAP BMP2 BMP7 COL2A1 F2 PTH
2 endoplasmic reticulum lumen GO:0005788 9.46 BGLAP COL2A1 F2 SERPINC1
3 extracellular space GO:0005615 9.36 BGLAP BMP2 BMP7 COL2A1 F2 PTH

Biological processes related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.83 ABCB1 BGLAP MTHFR PTH TNFRSF11B
2 osteoblast differentiation GO:0001649 9.82 BGLAP BMP2 RUNX2
3 BMP signaling pathway GO:0030509 9.8 BMP2 BMP7 RUNX2
4 regulation of signaling receptor activity GO:0010469 9.76 BMP2 BMP7 F2 PTH SERPINE1 TNFRSF11B
5 cartilage development GO:0051216 9.75 BMP2 BMP7 COL2A1
6 positive regulation of osteoblast differentiation GO:0045669 9.73 BMP2 BMP7 RUNX2
7 odontogenesis of dentin-containing tooth GO:0042475 9.72 BMP2 BMP7 RUNX2
8 bone development GO:0060348 9.71 BGLAP COL2A1 TNFSF11
9 osteoblast development GO:0002076 9.66 BGLAP RUNX2
10 mammary gland alveolus development GO:0060749 9.65 TNFSF11 VEGFA
11 regulation of osteoclast differentiation GO:0045670 9.65 BGLAP TNFSF11
12 positive regulation of ossification GO:0045778 9.65 BMP2 PTH
13 response to inorganic substance GO:0010035 9.64 BGLAP TNFRSF11B
14 positive regulation of blood coagulation GO:0030194 9.63 F2 SERPINE1
15 chondrocyte differentiation GO:0002062 9.63 BMP2 COL2A1 RUNX2
16 regulation of blood coagulation GO:0030193 9.62 F2 SERPINC1
17 oxidative demethylation GO:0070989 9.62 CYP2C8 CYP3A4
18 embryonic skeletal joint morphogenesis GO:0060272 9.61 BMP7 COL2A1
19 peptidyl-glutamic acid carboxylation GO:0017187 9.61 BGLAP F2
20 negative regulation of fibrinolysis GO:0051918 9.6 F2 SERPINE1
21 mesenchymal cell differentiation GO:0048762 9.59 BMP2 BMP7
22 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.58 BMP2 RUNX2
23 positive regulation of bone mineralization GO:0030501 9.58 BMP2 BMP7 PTH
24 proteoglycan metabolic process GO:0006029 9.57 BMP2 COL2A1
25 cellular response to BMP stimulus GO:0071773 9.56 BMP2 BMP7 COL2A1 RUNX2
26 bone resorption GO:0045453 9.54 ACP5 PTH TNFSF11
27 lipid hydroxylation GO:0002933 9.52 CYP2C8 CYP3A4
28 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.51 BMP2 RUNX2
29 response to vitamin D GO:0033280 9.5 BGLAP BMP7 PTH
30 mesenchyme development GO:0060485 9.48 BMP2 BMP7
31 ossification GO:0001503 9.43 BGLAP BMP2 BMP7 COL2A1 RUNX2 TNFSF11
32 skeletal system development GO:0001501 9.17 BGLAP BMP2 BMP7 COL2A1 PTH RUNX2
33 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 BMP2 BMP7 PTH RUNX2 SERPINE1 TNFSF11

Molecular functions related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 BMP2 BMP7 F2 VEGFA
2 heparin binding GO:0008201 9.46 BMP7 F2 SERPINC1 VEGFA
3 BMP receptor binding GO:0070700 9.37 BMP2 BMP7
4 estrogen 16-alpha-hydroxylase activity GO:0101020 9.32 CYP2C8 CYP3A4
5 cytokine activity GO:0005125 9.02 BMP2 BMP7 TNFRSF11B TNFSF11 VEGFA
6 caffeine oxidase activity GO:0034875 8.96 CYP2C8 CYP3A4

Sources for Osteonecrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....